NCT05808335View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

PHASE2UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

March 27, 2024

Study Completion Date

December 4, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

Standard of care

"The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)"

Trial Locations (4)

Unknown

RECRUITING

Chung-Ang University Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

Sponsors

Lead Sponsor

ImmuneMed, Inc.
All Listed Sponsors
lead

ImmuneMed, Inc.

INDUSTRY